Arrowpoint Investment Partners’s Structure Therapeutics GPCR Stock Holding History

Arrowpoint Investment Partners’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$202K	Buy	+4,190	New	+$287K	0.18%	70

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Arrowpoint Investment Partners's GPCR Position: Q1 2026 in Review

Arrowpoint Investment Partners opened a new position in Structure Therapeutics (GPCR) in Q1 2026: 4,190 shares worth $202K. The stake represents 0.18% of the portfolio and ranks #70 among its holdings.

196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Arrowpoint Investment Partners held 4,190 shares of Structure Therapeutics worth $202K as of Q1 2026.
Structure Therapeutics was a new Arrowpoint Investment Partners position in Q1 2026.
Structure Therapeutics made up 0.18% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #70 holding.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.